ArticleIndian journal of endocrinology and metabolism
Efficacy of Fixed Low-Dose Weekly Subcutaneous Testosterone Self-Administration in Transgender Male Patients in India.
Article in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Testosterone (T) is commonly administered intramuscularly to treat hypogonadal males and female-to-male (FTM) transgender patients. Intramuscular testosterone administration has various drawbacks, including discomfort, bruising, pain, and the need to be administered by a healthcare professional. Self-administered subcutaneous route may be a convenient, safe, and effective alternative. The current study assesses the efficacy and safety of low-dose (50 mg) weekly subcutaneous testosterone administration among FTM transgender. Methods: The current retrospective cohort study included adult FTM transgender subjects. Participants were administered T-cypionate weekly at a dose of 50 mg and followed up for 6 months. At the end of the follow-up, serum concentrations of testosterone, oestradiol (E2), and the number of participants achieving target E2 (<50 pg/mL) and testosterone (300-700 ng/mL) levels were determined. Results: The patient cohort consisted of 22 FTM transgender subjects. The average age was 29 years and body mass index was 26.3 ± 3.3 kg/m Conclusion: Weekly self-administered 50 mg low-dose, subcutaneous testosterone injection was effective in achieving target testosterone and oestradiol levels in FTM transgender subjects, without significant safety issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.